The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis
Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis...
Gespeichert in:
Veröffentlicht in: | PloS one 2017-11, Vol.12 (11), p.e0187902-e0187902 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e0187902 |
---|---|
container_issue | 11 |
container_start_page | e0187902 |
container_title | PloS one |
container_volume | 12 |
creator | Wu, Yingcheng Xu, Ran Jia, Keren Shi, Hui |
description | Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis was conducted on the efficacy of CAR in animal models for solid tumors.
The authors searched PubMed/Medline, Embase, and Google scholar up to April 2017. HR for survival was extracted based on the survival curve. The authors used fixed effect models to combine the results of all the trials. Heterogeneity was assessed by I-square statistic. Quality assessment was conducted following the Stroke Therapy Academic Industry Roundtable standard. Publication bias was assessed using Egger's test.
Eleven trials were included, including 54 experiments with a total of 362 animals involved. CAR immunotherapy significantly improved the survival of animals (HR: 0.25, 95% CI: 0.13-0.37, P < 0.001). The quality assessment revealed that no study reported whether allocation concealment and blinded outcome assessment were conducted, and only five studies implemented randomization.
This meta-analysis indicated that CAR therapy may be a potential clinical strategy in treating solid tumors. |
doi_str_mv | 10.1371/journal.pone.0187902 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1964557298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A514570587</galeid><doaj_id>oai_doaj_org_article_700f05319637407d8c8457f499231f87</doaj_id><sourcerecordid>A514570587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593t-63b99c1c2d6dc99a1bb4ff33e31c9a8ca0bb879dd3101c1023ad6cdc1a4579273</originalsourceid><addsrcrecordid>eNptUt1q2zAYNWNj7bq9wdgEu-kukkmWZVm9GISwn0JhMLprIUufEgXLyiS7Iy-w556SuKUZRRcW8vn5zscpircEzwnl5NMmjLFX3Xwbephj0nCBy2fFORG0nNUlps8f3c-KVyltMGa0qeuXxVkpSEVwyc-Lv7drQGCt00rvULBIr52H6DRS_eBW0KMIGrZDiOhyufj5ETnvxz4Ma4hqu0OuzzjnVYd8MNAlZDMwhc4ZNIw-xHSFFijt0gBeDVk0wp2DP5ljkIdBzVROsEsuvS5eWNUleDN9L4pfX7_cLr_Pbn58u14ubmaaCTrMatoKoYkuTW20EIq0bWUtpUCJFqrRCrdtXoQxlGCic0KqTK2NJqpiXJScXhTvj7rbLiQ5rTBJIuqKMV6KJiOujwgT1EZuYw4XdzIoJw8PIa6kijlKB5JjbPNKM5nyCnPT6Cbb2EqIkhLb7N0-T25j68Fo6IeouhPR0z-9W8tVuJOsbjindRa4nARi-D1CGqR3SUPXqR7CeJiblYw1Yu_14T_o0-km1ErlAK63IfvqvahcMJKnx-ww9_wJVD4GvNO5b9bl9xNCdSToGFKKYB8yEiz3bb0fRu7bKqe2Ztq7x_t5IN3Xk_4DISLnpg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1964557298</pqid></control><display><type>article</type><title>The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wu, Yingcheng ; Xu, Ran ; Jia, Keren ; Shi, Hui</creator><contributor>Pizzo, Salvatore V</contributor><creatorcontrib>Wu, Yingcheng ; Xu, Ran ; Jia, Keren ; Shi, Hui ; Pizzo, Salvatore V</creatorcontrib><description>Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis was conducted on the efficacy of CAR in animal models for solid tumors.
The authors searched PubMed/Medline, Embase, and Google scholar up to April 2017. HR for survival was extracted based on the survival curve. The authors used fixed effect models to combine the results of all the trials. Heterogeneity was assessed by I-square statistic. Quality assessment was conducted following the Stroke Therapy Academic Industry Roundtable standard. Publication bias was assessed using Egger's test.
Eleven trials were included, including 54 experiments with a total of 362 animals involved. CAR immunotherapy significantly improved the survival of animals (HR: 0.25, 95% CI: 0.13-0.37, P < 0.001). The quality assessment revealed that no study reported whether allocation concealment and blinded outcome assessment were conducted, and only five studies implemented randomization.
This meta-analysis indicated that CAR therapy may be a potential clinical strategy in treating solid tumors.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0187902</identifier><identifier>PMID: 29141027</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Animal models ; Animals ; Antigens ; Bias ; Biology and Life Sciences ; Care and treatment ; Chimeric antigen receptors ; Clinical trials ; Cytokines ; Disease Models, Animal ; Gene therapy ; Humans ; Immunology ; Immunotherapy ; Lymphocytes ; Medical research ; Medicine and Health Sciences ; Meta-analysis ; Methods ; Neoplasms - therapy ; Ovarian cancer ; Pancreatic cancer ; Physical Sciences ; Quality assessment ; Quality control ; Receptors, Antigen - immunology ; Receptors, Antigen - therapeutic use ; Recombinant Fusion Proteins - immunology ; Recombinant Fusion Proteins - therapeutic use ; Research and Analysis Methods ; Scientific papers ; Search engines ; Solid tumors ; Stroke ; Studies ; Survival ; Therapy ; Thoracic surgery ; Tumors</subject><ispartof>PloS one, 2017-11, Vol.12 (11), p.e0187902-e0187902</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><rights>2017 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Wu et al 2017 Wu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593t-63b99c1c2d6dc99a1bb4ff33e31c9a8ca0bb879dd3101c1023ad6cdc1a4579273</citedby><cites>FETCH-LOGICAL-c593t-63b99c1c2d6dc99a1bb4ff33e31c9a8ca0bb879dd3101c1023ad6cdc1a4579273</cites><orcidid>0000-0001-9473-546X ; 0000-0001-6446-4160</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687736/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687736/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2100,2926,23865,27923,27924,53790,53792,79371,79372</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29141027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Pizzo, Salvatore V</contributor><creatorcontrib>Wu, Yingcheng</creatorcontrib><creatorcontrib>Xu, Ran</creatorcontrib><creatorcontrib>Jia, Keren</creatorcontrib><creatorcontrib>Shi, Hui</creatorcontrib><title>The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis was conducted on the efficacy of CAR in animal models for solid tumors.
The authors searched PubMed/Medline, Embase, and Google scholar up to April 2017. HR for survival was extracted based on the survival curve. The authors used fixed effect models to combine the results of all the trials. Heterogeneity was assessed by I-square statistic. Quality assessment was conducted following the Stroke Therapy Academic Industry Roundtable standard. Publication bias was assessed using Egger's test.
Eleven trials were included, including 54 experiments with a total of 362 animals involved. CAR immunotherapy significantly improved the survival of animals (HR: 0.25, 95% CI: 0.13-0.37, P < 0.001). The quality assessment revealed that no study reported whether allocation concealment and blinded outcome assessment were conducted, and only five studies implemented randomization.
This meta-analysis indicated that CAR therapy may be a potential clinical strategy in treating solid tumors.</description><subject>Animal models</subject><subject>Animals</subject><subject>Antigens</subject><subject>Bias</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Chimeric antigen receptors</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Disease Models, Animal</subject><subject>Gene therapy</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Meta-analysis</subject><subject>Methods</subject><subject>Neoplasms - therapy</subject><subject>Ovarian cancer</subject><subject>Pancreatic cancer</subject><subject>Physical Sciences</subject><subject>Quality assessment</subject><subject>Quality control</subject><subject>Receptors, Antigen - immunology</subject><subject>Receptors, Antigen - therapeutic use</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Research and Analysis Methods</subject><subject>Scientific papers</subject><subject>Search engines</subject><subject>Solid tumors</subject><subject>Stroke</subject><subject>Studies</subject><subject>Survival</subject><subject>Therapy</subject><subject>Thoracic surgery</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNptUt1q2zAYNWNj7bq9wdgEu-kukkmWZVm9GISwn0JhMLprIUufEgXLyiS7Iy-w556SuKUZRRcW8vn5zscpircEzwnl5NMmjLFX3Xwbephj0nCBy2fFORG0nNUlps8f3c-KVyltMGa0qeuXxVkpSEVwyc-Lv7drQGCt00rvULBIr52H6DRS_eBW0KMIGrZDiOhyufj5ETnvxz4Ma4hqu0OuzzjnVYd8MNAlZDMwhc4ZNIw-xHSFFijt0gBeDVk0wp2DP5ljkIdBzVROsEsuvS5eWNUleDN9L4pfX7_cLr_Pbn58u14ubmaaCTrMatoKoYkuTW20EIq0bWUtpUCJFqrRCrdtXoQxlGCic0KqTK2NJqpiXJScXhTvj7rbLiQ5rTBJIuqKMV6KJiOujwgT1EZuYw4XdzIoJw8PIa6kijlKB5JjbPNKM5nyCnPT6Cbb2EqIkhLb7N0-T25j68Fo6IeouhPR0z-9W8tVuJOsbjindRa4nARi-D1CGqR3SUPXqR7CeJiblYw1Yu_14T_o0-km1ErlAK63IfvqvahcMJKnx-ww9_wJVD4GvNO5b9bl9xNCdSToGFKKYB8yEiz3bb0fRu7bKqe2Ztq7x_t5IN3Xk_4DISLnpg</recordid><startdate>20171115</startdate><enddate>20171115</enddate><creator>Wu, Yingcheng</creator><creator>Xu, Ran</creator><creator>Jia, Keren</creator><creator>Shi, Hui</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9473-546X</orcidid><orcidid>https://orcid.org/0000-0001-6446-4160</orcidid></search><sort><creationdate>20171115</creationdate><title>The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis</title><author>Wu, Yingcheng ; Xu, Ran ; Jia, Keren ; Shi, Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593t-63b99c1c2d6dc99a1bb4ff33e31c9a8ca0bb879dd3101c1023ad6cdc1a4579273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Antigens</topic><topic>Bias</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Chimeric antigen receptors</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Disease Models, Animal</topic><topic>Gene therapy</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Meta-analysis</topic><topic>Methods</topic><topic>Neoplasms - therapy</topic><topic>Ovarian cancer</topic><topic>Pancreatic cancer</topic><topic>Physical Sciences</topic><topic>Quality assessment</topic><topic>Quality control</topic><topic>Receptors, Antigen - immunology</topic><topic>Receptors, Antigen - therapeutic use</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Research and Analysis Methods</topic><topic>Scientific papers</topic><topic>Search engines</topic><topic>Solid tumors</topic><topic>Stroke</topic><topic>Studies</topic><topic>Survival</topic><topic>Therapy</topic><topic>Thoracic surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Yingcheng</creatorcontrib><creatorcontrib>Xu, Ran</creatorcontrib><creatorcontrib>Jia, Keren</creatorcontrib><creatorcontrib>Shi, Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Yingcheng</au><au>Xu, Ran</au><au>Jia, Keren</au><au>Shi, Hui</au><au>Pizzo, Salvatore V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-11-15</date><risdate>2017</risdate><volume>12</volume><issue>11</issue><spage>e0187902</spage><epage>e0187902</epage><pages>e0187902-e0187902</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis was conducted on the efficacy of CAR in animal models for solid tumors.
The authors searched PubMed/Medline, Embase, and Google scholar up to April 2017. HR for survival was extracted based on the survival curve. The authors used fixed effect models to combine the results of all the trials. Heterogeneity was assessed by I-square statistic. Quality assessment was conducted following the Stroke Therapy Academic Industry Roundtable standard. Publication bias was assessed using Egger's test.
Eleven trials were included, including 54 experiments with a total of 362 animals involved. CAR immunotherapy significantly improved the survival of animals (HR: 0.25, 95% CI: 0.13-0.37, P < 0.001). The quality assessment revealed that no study reported whether allocation concealment and blinded outcome assessment were conducted, and only five studies implemented randomization.
This meta-analysis indicated that CAR therapy may be a potential clinical strategy in treating solid tumors.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>29141027</pmid><doi>10.1371/journal.pone.0187902</doi><orcidid>https://orcid.org/0000-0001-9473-546X</orcidid><orcidid>https://orcid.org/0000-0001-6446-4160</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2017-11, Vol.12 (11), p.e0187902-e0187902 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1964557298 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Animal models Animals Antigens Bias Biology and Life Sciences Care and treatment Chimeric antigen receptors Clinical trials Cytokines Disease Models, Animal Gene therapy Humans Immunology Immunotherapy Lymphocytes Medical research Medicine and Health Sciences Meta-analysis Methods Neoplasms - therapy Ovarian cancer Pancreatic cancer Physical Sciences Quality assessment Quality control Receptors, Antigen - immunology Receptors, Antigen - therapeutic use Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - therapeutic use Research and Analysis Methods Scientific papers Search engines Solid tumors Stroke Studies Survival Therapy Thoracic surgery Tumors |
title | The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A04%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20efficacy%20of%20chimeric%20antigen%20receptor%20(CAR)%20immunotherapy%20in%20animal%20models%20for%20solid%20tumors:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Wu,%20Yingcheng&rft.date=2017-11-15&rft.volume=12&rft.issue=11&rft.spage=e0187902&rft.epage=e0187902&rft.pages=e0187902-e0187902&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0187902&rft_dat=%3Cgale_plos_%3EA514570587%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1964557298&rft_id=info:pmid/29141027&rft_galeid=A514570587&rft_doaj_id=oai_doaj_org_article_700f05319637407d8c8457f499231f87&rfr_iscdi=true |